in this issue
Markets :: Fine Chemicals/Biotech :: Industrial Biotech
Fine Chemicals: Biologics Bounce Back
1:01 PM MST | January 18, 2008 | Deepti Ramesh with Alex Scott
It has been a long time coming, but contract manufacturers are finally beginning to reap financial rewards from their investment in large-molecule therapeutic drugs, also known as biologics or biopharmaceuticals. There have been casualties along the way, however, mainly due to the failure of drugs under development to reach the market. Casualties include Cambrex, which one year ago sold its biologics activities to Lonza, and DSM, which also in the past year was forced to shutter a large-scale biologics manufacturing plant at Montreal and subsequently sell the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee